Fig. S1

STLC treatment phenocopies kif11^-/- mutants without causing additional morphological deformations. Lateral views of wild type neural tubes after treatment from 5hpf to 30hpf with various concentrations of either the vehicle control (dimethyl sulfoxide, A-E) or S-trityl-L-cysteine (STLC, F-J). Astroglial and axon changes were visualized by labeling for Gfap and acetylated Tubulin (AT). No change in radial glial soma number was seen in DMSO control embryos at any concentration tested. Gfap+ floorplate somas (arrowheads) were only seen at higher concentrations of STLC (H-J). (K) Quantification of the average Gfap+ soma number following Kif11 inhibition. The lowest concentration of DME (0.5mM) caused an increase in GFAP+ cell bodies, however extreme gross morphological defects were also noted therefore this drug was not further processed. Gfap+ cell body number was increased in STLC concentrations higher than 0.625mM (grey bars, asterisks). (L) A maximum concentration of 0.875mM phenocopied the kif11 mutant. No additive effects were seen or quantified when kif11^-/- mutants were treated with 0.875mM STLC (L, black bars, data not shown). There was no statistically significant difference seen between STLC-treated wild type, heterozygous kif11^+/-, and homozygous kif11^-/- (L). Error bars delineate the standard error of the mean. Asterisks indicate a statistical significance (t-test, two tailed, assuming equal variances, p<0.05).